WO2006083874A3 - Vaccine delivery compositions and methods of use - Google Patents

Vaccine delivery compositions and methods of use Download PDF

Info

Publication number
WO2006083874A3
WO2006083874A3 PCT/US2006/003412 US2006003412W WO2006083874A3 WO 2006083874 A3 WO2006083874 A3 WO 2006083874A3 US 2006003412 W US2006003412 W US 2006003412W WO 2006083874 A3 WO2006083874 A3 WO 2006083874A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine delivery
immune response
delivery compositions
methods
polyester
Prior art date
Application number
PCT/US2006/003412
Other languages
French (fr)
Other versions
WO2006083874A2 (en
Inventor
William G Tunell
Vassil P Vassilev
Kristin M Defife
Hong Li
Zaza D Gomurashvili
Ramaz Katsarava
Original Assignee
Medivas Llc
William G Tunell
Vassil P Vassilev
Kristin M Defife
Hong Li
Zaza D Gomurashvili
Ramaz Katsarava
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivas Llc, William G Tunell, Vassil P Vassilev, Kristin M Defife, Hong Li, Zaza D Gomurashvili, Ramaz Katsarava filed Critical Medivas Llc
Priority to AU2006210863A priority Critical patent/AU2006210863A1/en
Priority to EP06734124A priority patent/EP1865983A2/en
Priority to CA002595783A priority patent/CA2595783A1/en
Priority to JP2007553357A priority patent/JP2008532929A/en
Publication of WO2006083874A2 publication Critical patent/WO2006083874A2/en
Priority to EP07762672A priority patent/EP1986685A4/en
Priority to CA002676601A priority patent/CA2676601A1/en
Priority to JP2008553341A priority patent/JP2009525341A/en
Priority to PCT/US2007/002704 priority patent/WO2007089870A2/en
Priority to US11/701,229 priority patent/US20080160089A1/en
Publication of WO2006083874A3 publication Critical patent/WO2006083874A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G23/00—Compounds of titanium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Environmental & Geological Engineering (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Manufacturing & Machinery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

The present invention provides synthetic vaccine delivery compositions based on polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers for stimulating an immune response to a variety of pathogenic organisms and tumor cells in humans and other mammals. The vaccine delivery compositions are formulated as a liquid dispersion of polymer particles or molecules including class I or class II antigen peptides derived from organism or tumor cell proteins, which are taken up by antigen presenting cells of the mammal to induce an immune response in the mammal. Methods of inducing an immune response to the pathogenic organism or tumor cells in the invention compositions are also included.
PCT/US2006/003412 2003-10-14 2006-01-31 Vaccine delivery compositions and methods of use WO2006083874A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2006210863A AU2006210863A1 (en) 2005-02-01 2006-01-31 Vaccine delivery compositions and methods of use
EP06734124A EP1865983A2 (en) 2005-02-01 2006-01-31 Vaccine delivery compositions and methods of use
CA002595783A CA2595783A1 (en) 2005-02-01 2006-01-31 Vaccine delivery compositions and methods of use
JP2007553357A JP2008532929A (en) 2005-02-01 2006-01-31 Vaccine delivery compositions and methods of use
EP07762672A EP1986685A4 (en) 2006-01-31 2007-01-31 Vaccine delivery compositions and methods of use
CA002676601A CA2676601A1 (en) 2006-01-31 2007-01-31 Vaccine delivery compositions and methods of use
JP2008553341A JP2009525341A (en) 2006-01-31 2007-01-31 Vaccine delivery compositions and methods of use
PCT/US2007/002704 WO2007089870A2 (en) 2006-01-31 2007-01-31 Vaccine delivery compositions and methods of use
US11/701,229 US20080160089A1 (en) 2003-10-14 2007-01-31 Vaccine delivery compositions and methods of use

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US64928905P 2005-02-01 2005-02-01
US60/649,289 2005-02-01
US68757005P 2005-06-03 2005-06-03
US60/687,570 2005-06-03
US68900305P 2005-06-08 2005-06-08
US60/689,003 2005-06-08
US71995005P 2005-09-22 2005-09-22
US60/719,950 2005-09-22
US74218805P 2005-12-02 2005-12-02
US60/742,188 2005-12-02
US74848605P 2005-12-07 2005-12-07
US60/748,486 2005-12-07
US75917906P 2006-01-13 2006-01-13
US60/759,179 2006-01-13

Publications (2)

Publication Number Publication Date
WO2006083874A2 WO2006083874A2 (en) 2006-08-10
WO2006083874A3 true WO2006083874A3 (en) 2009-04-23

Family

ID=36777844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/003412 WO2006083874A2 (en) 2003-10-14 2006-01-31 Vaccine delivery compositions and methods of use

Country Status (6)

Country Link
EP (1) EP1865983A2 (en)
JP (1) JP2008532929A (en)
KR (1) KR20070101341A (en)
AU (1) AU2006210863A1 (en)
CA (1) CA2595783A1 (en)
WO (1) WO2006083874A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652504B2 (en) 2005-09-22 2014-02-18 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
US9102830B2 (en) 2005-09-22 2015-08-11 Medivas, Llc Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
CA2670355A1 (en) * 2005-11-21 2008-04-24 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
CA2676601A1 (en) * 2006-01-31 2007-08-09 Medivas, Llc Vaccine delivery compositions and methods of use
EP2068937A2 (en) * 2006-09-05 2009-06-17 Medivas, LLC Polymer-stabilized liposomal compositions and methods of use
EP2017006A1 (en) 2007-07-20 2009-01-21 Koninklijke Philips Electronics N.V. Microfluidic methods and systems for use in detecting analytes
CN102014874A (en) * 2008-03-04 2011-04-13 流体科技公司 Immunomodulator particles and methods of treating
US20100004390A1 (en) * 2008-05-07 2010-01-07 Medivas, Llc Biodegradable metal-chelating polymers and vaccines
EP2404618A1 (en) 2010-07-07 2012-01-11 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Immunomodulatory protein constructs with a helical polymeric backbone.
KR101327181B1 (en) * 2011-02-28 2013-11-06 이연제약주식회사 Gene Delivery Complex Comprising Renal Cell-Specific Peptide and Polyester Amine and Composition Comprising The Same for Preventing or Treating of Renal Fibrosis.
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
EP2723800B1 (en) 2011-06-23 2015-10-07 DSM IP Assets B.V. Micro- or nanoparticles comprising a biodegradable polyesteramide copolymer for use in the delivery of bioactive agents
AU2015366355B2 (en) 2014-12-18 2020-05-28 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
WO2016176761A1 (en) * 2015-05-01 2016-11-10 Immunovaccine Technologies Inc., Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
BR112019020853A2 (en) * 2017-04-04 2020-05-12 Avidea Technologies, Inc. PEPTIDE BASED VACCINES, MANUFACTURING METHODS AND USES OF THE SAME TO INDUCT AN IMMUNE RESPONSE
US20210113705A1 (en) * 2018-05-22 2021-04-22 Avidea Technologies, Inc. Improved methods of manufacturing peptide-based vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018477A2 (en) * 2000-08-30 2002-03-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018477A2 (en) * 2000-08-30 2002-03-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652504B2 (en) 2005-09-22 2014-02-18 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
US9102830B2 (en) 2005-09-22 2015-08-11 Medivas, Llc Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use

Also Published As

Publication number Publication date
WO2006083874A2 (en) 2006-08-10
CA2595783A1 (en) 2006-08-10
KR20070101341A (en) 2007-10-16
JP2008532929A (en) 2008-08-21
EP1865983A2 (en) 2007-12-19
AU2006210863A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
WO2006083874A3 (en) Vaccine delivery compositions and methods of use
WO2007089870A3 (en) Vaccine delivery compositions and methods of use
EP3909973A3 (en) Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof
MY162559A (en) Human anti-il-23 antibodies, compositions, methods and uses
WO2010051274A3 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
WO2007039192A3 (en) Compositions and methods for treating tumors presenting survivin antigens
DK2343320T3 (en) ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF
MX2019002345A (en) Artificial nucleic acid molecules for improved protein or peptide expression.
MX357674B (en) Biosynthetic proline/alanine random coil polypeptides and their uses.
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (en) Albumin fusion proteins.
ATE494303T1 (en) TUMOR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND ASSOCIATED CANCER VACCINE
WO2007005955A3 (en) Anti-il-23 antibodies, compositions, methods and uses
EP3797583A3 (en) Methods and compositions for gene expression in plants
MY156286A (en) Human il-23 antigen binding proteins
WO2008052173A3 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2012083078A3 (en) Croos-linked peptides and proteins, methods of making same, and uses thereof
AR079114A1 (en) ANTI-ORAI1 ANTIGEN LINK PROTEINS AND USES OF THE SAME
IN2012DN03368A (en)
MXPA06008217A (en) Lawsonia intracellularis subunit vaccines.
EP2264058A3 (en) Plasmodium liver stage antigens
EP2481748A3 (en) Foxp3 peptide vaccine
WO2007098060A3 (en) Methods and agents for modulating an immune response
MX2015005636A (en) Novel immunotherapeutic molecules and uses thereof.
WO2013128409A3 (en) De novo integron recombination sites and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680003526.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 4368/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006210863

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006210863

Country of ref document: AU

Date of ref document: 20060131

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2595783

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007553357

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006734124

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077019121

Country of ref document: KR